European Pharmaceutical Review
DECEMBER 1, 2022
According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. billion during 2028. Challenges facing mRNA therapeutics.
Pharmaceutical Technology
OCTOBER 5, 2022
In 2010, two patients with end-stage refractory chronic lymphocytic leukaemia (CLL) were administered Novartis’ autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah (tisagenlecleucel), as part of a Phase I trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 16, 2022
Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.
Pharmaceutical Technology
DECEMBER 11, 2022
Richter’s transformation (RT) is a rare blood cancer arising in up to 10% of patients with chronic lymphocytic leukemia (CLL) and presenting as aggressive lymphoma, typically as diffuse large B-cell lymphoma (DLBCL). Among the enrolled patients, 68 were previously treated and seven were newly diagnosed. The mOS was 13.1
pharmaphorum
SEPTEMBER 12, 2022
The digital health market is being driven by expansion of digital connectivity, declining cost of sensors and other technology components, and an increase in patient engagement, and is predicted to reach a value of $450 billion by 2028, according to the company.
Pharmaceutical Technology
AUGUST 22, 2022
When it comes to pharmaceutical, nutritional or cosmeceutical dosing, some of the most crucial parameters are safety, product effectiveness and patient adherence. Softgel capsules, containing a liquid, paste or emulsion active ingredient, are trusted and favoured by many patients. billion by 2028, at a CAGR of 12.6%.
Clarivate
OCTOBER 25, 2023
The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs.
Expert insights. Personalized for you.
90 
Let's personalize your content